Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea · Delayed Price · Currency is KRW 3,035.00
-70.00 (-2.25%)
At close: May 20, 2026
Kangstem Biotech Revenue
In the year 2025, Kangstem Biotech had annual revenue of 3.57B KRW, down -53.88%. Kangstem Biotech had revenue of 3.40B in the quarter ending December 31, 2024, a decrease of -1.10%.
Revenue
3.57B
Revenue Growth
-70.62%
P/S Ratio
79.90
Revenue / Employee
36.83M
Employees
97
Market Cap
285.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.57B | -4.17B | -53.88% |
| Dec 31, 2024 | 7.75B | -4.96B | -39.03% |
| Dec 31, 2023 | 12.70B | -3.60B | -22.06% |
| Dec 31, 2022 | 16.30B | 3.90B | 31.41% |
| Dec 31, 2021 | 12.40B | 3.27B | 35.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 56.67B |
| Cell Biotech | 53.13B |
| CORESTEMCHEMON | 20.16B |
| TiumBio | 12.29B |
| QuadMedicine | 10.70B |
| Inventage Lab | 2.94B |
| Ensol Biosciences | 537.46M |
| ViGenCell | 278.95M |